Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism, lipid profiles and hepatic function

Journal of Diabetes Investigation

Volumn 2, Issue 4, 2011, Pages 276-279

  Nakamura, Akinobu ^a   Shimazaki, Hiroko ^b   Ohyama, Sumika ^b   Eiki, Junichi ^b   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Glucokinase; Glucokinase activator; Lipid profiles

Indexed keywords

3 (2 HYDROXY 1 METHYLETHOXY) 5 [4 (METHYLSULFONYL)PHENOXY] N 1,3 THIAZOL 2 YLBENZAMIDE; ALANINE AMINOTRANSFERASE; CHOLESTEROL; ENZYME ACTIVATOR; FATTY ACID; GLUCOKINASE; GLUCOSE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; LIPID DIET; LIPID METABOLISM; LIVER FUNCTION; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84862211353     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00104.x     Document Type: Article

References (11)

1. Matschinsky FM, Magnuson MA, Zelent D, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes 2006; 55: 1-12.
2. Grimsby J, Sarabu R, Corbett WL, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003; 301: 370-373.
3. Matschinsky FM. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009; 8: 399-416.
4. Nakamura A, Terauchi Y, Ohyama S, et al. Impact of small molecule glucokinase activator on glucose metabolism, beta cell function and mass. Endocrinology 2009; 150: 1147-1154.
5. Ferre T, Riu E, Franckhauser S, et al. Long-term overexpression of glucokinase in the liver of transgenic mice leads to insulin resistance. Diabetologia 2003; 46: 1662-1668.
6. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
7. Iino T, Hashimoto N, Sasaki K, et al. Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy. Bioorg Med Chem 2009; 17: 3800-3809.
8. Terauchi Y, Takamoto I, Kubota N, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007; 117: 246-257.
9. Futamura M, Hosaka H, Kadotani A, et al. An allosteric activator of glucokinase impairs the interaction of glucokinase and glucokinase regulatory protein and regulates glucose metabolism. J Biol Chem 2006; 281: 37668-37674.
10. Shiota M, Postic C, Fujimoto Y, et al. Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. Diabetes 2001; 50: 622-629.
11. Ohyama S, Takano H, Iino T, et al. A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat. Eur J Pharmacol 2010; 640: 250-256.